Er Agile Therapeutics udbyttet sikkert?
Agile Therapeutics har øget udbyttet i 0 år.
Inden for de seneste 10 år har Agile Therapeutics øget denne med 0 % årligt sænket.
På 5-årssigt faldt udbetalingen med 0 %.
Analytikerne forventer en Udbyttereduktion på -100,000% for det igangværende regnskabsår.
Agile Therapeutics Aktienanalyse
Hvad laver Agile Therapeutics?
Agile Therapeutics Inc is a biopharmaceutical company specializing in the development of women's products. The company was founded in 1997 and is based in Princeton, New Jersey, USA.
Agile Therapeutics Inc focuses on manufacturing a unique range of women's products called the Women's Healthcare Division. These products aim to help women maintain their health and well-being by addressing their health issues and improving their quality of life.
The products of Agile Therapeutics target various areas, including birth control, menstrual discomfort, and frequent infections. The company offers a variety of products to meet a wide range of needs.
An important area in which Agile Therapeutics is active is birth control. The company has developed an innovative transdermal contraception system called Twirla, which is currently approved in the USA. In this system, the hormone Gestodene is absorbed through the skin, preventing pregnancy. The Twirla product is easy to use, safe, and effective. It may also offer several other benefits, such as higher tolerability compared to other contraceptive methods.
Agile Therapeutics has also developed other products aimed at improving women's quality of life. This includes the product AG200-15, marketed as a treatment for severe menstrual discomfort. It is a progesterone-based transdermal system that allows for continuous dosing over several weeks, thereby reducing menstrual discomfort.
Another product is AG890, marketed as a treatment for frequent vaginal infections such as yeast infections. This system aims to help women prevent or treat these infections and also aids in the prevention of recurring infections.
The business model of Agile Therapeutics is based on the development and commercialization of women's products that address a significant need in society. The company enters into strategic partnerships with other companies and institutions to effectively and efficiently market its products.
Agile Therapeutics also has a strong presence in research and development. Through intensive research efforts, the company has produced a range of innovative products that are in various stages of testing and trial. Agile Therapeutics works closely with the FDA (Food and Drug Administration) to ensure that its products meet all regulatory requirements.
Overall, Agile Therapeutics is an innovative company specializing in the development of women's products. With its focus on the health needs of women, the company aims to improve the quality of life for women worldwide. With a wide range of products and a strong business model, Agile Therapeutics is well-positioned for a promising future. Agile Therapeutics er et af de mest populære virksomheder på Eulerpool.com.Aktiespareplaner tilbyder en attraktiv mulighed for investorer at opbygge formue på lang sigt. En af de største fordele er den såkaldte cost-average-effekt: Ved regelmæssigt at investere et fast beløb i aktier eller aktiefonde, køber man automatisk flere andele, når priserne er lave, og færre, når de er høje. Dette kan føre til en mere fordelagtig gennemsnitspris per andel over tid. Desuden giver aktiespareplaner også småinvestorer adgang til dyre aktier, da de kan deltage med små beløb. Den regelmæssige investering fremmer også en disciplineret investeringsstrategi og hjælper med at undgå følelsesladede beslutninger, som impulsiv køb eller salg. Derudover drager investorer fordel af den potentielle værdistigning af aktierne samt af udbytteudlodninger, der kan geninvesteres, hvilket forstærker renters rente effekten og dermed væksten af det investerede kapital.